Amgen (AMGN) Long-Term Investments (2013 - 2014)
Amgen (AMGN) posted quarterly Long-Term Investments of $3.4 billion for Q1 2014, little changed quarter-over-quarter from $3.4 billion in Q4 2013.
Amgen (AMGN) Long-Term Investments (2013 - 2014) Analysis & Trends
Amgen's Long-Term Investments history runs 2 years deep, the most recent figure standing at $3.4 billion for Q1 2014.
- In Q1 2014, Long-Term Investments changed N/A year-over-year to $3.4 billion; the TTM figure through Mar 2014 stood at $3.4 billion (changed N/A YoY), while the FY2013 annual figure was $3.4 billion, changed N/A from the prior year.
- Long-Term Investments for Q1 2014 stood at $3.4 billion, roughly flat from $3.4 billion in the prior quarter.
- The five-year high for Long-Term Investments was $3.4 billion in Q1 2014, with the low at $3.4 billion in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 3.73 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 3.41 Bn |
| Dec 31, 2013 | 3.41 Bn |
| Sep 30, 2013 | 3.41 Bn |